ASBISc Enterprises : 2023 Q1 Presentation

BACK TO GROWTH, BACK TO BUSINESS

ASBIS DELIVERS ITS MOST PROFITABLE EVER QUARTER 1

Q1 2023 RESULTS

TABLE OF CONTENT

ASBIS - Q1 2023 OVERVIEW FINANCIAL RESULTS IN Q1 2023 FINANCIAL FORECAST FOR 2023 DIVIDEND FOR 2022 SUMMARY

APPENDIX

2

Q1 2023 KEY BUSINESS EVENTS

STRONG MONTHLY

REVENUES

BUSINESS GROWTH

FINAL DIVIDEND

AMBITIOUS FORECAST

Very strong Q1 of 2023 for ASBIS. The Company has beaten its March record-breaking revenues reaching an immense 30% growth rate.

• ASBIS has established a subsidiary in Greece, ASBIS Hellas S.A.
• ASBIS has invested in Theramir LTD - biotech company which develops stem cell and RNA based technologies for the diagnosis and treatment of cancer disease
• Breezy, a subsidiary of ASBIS, due to the dynamic development, started operating on two more markets: Poland and Moldova
• ASBIS doubled its robotic commercial division - ASBIS Robotic Solutions (AROS) and started operations of this division in new countries such as Hungary and Bulgaria as well as in the Middle East and North Africa (MENA Region).

Annual General Meeting of Shareholders decided to pay out a final dividend from the Company's 2022 profits for the amount of USD 0.25 per share.

The Company announced its financial forecast for 2023:

:

• revenues between US$ 3.0 and US$ 3.2 billion
• net profit after tax between US$ 78.0 and US$ 82.0 million.

3

ASBIS IN Q1 2023

Subsidiaries in 28 countries

Revenue $ 722 m

20 B2B e-shops

• B2C e-commerce

20 000

active customers in 60 countries

4 Distribution centers

Over

240

vendors

• 485 employees

110 000 products in portfolio

60%

Online transactions

4

TABLE OF CONTENT

ASBIS - Q1 2023 OVERVIEW FINANCIAL RESULTS IN Q1 2023 FINANCIAL FORECAST FOR 2023 DIVIDEND FOR 2022 SUMMARY

APPENDIX

5